Supplements

Newborn Screening for Spinal Muscular Atrophy in the United States

Publish date: December 22, 2021

 

Click here to read the supplement

Newborn screening for spinal muscular atrophy (SMA) is essential to achieve optimal outcomes for patients with SMA by facilitating early identification and treatment before the onset of irreversible motor neuron loss.

Recommended Reading

New steroid dosing regimen for myasthenia gravis
MDedge Neurology
FDA approves first targeted treatment for rare DMD mutation
MDedge Neurology
Neurologic disorders ubiquitous and rising in the U.S.
MDedge Neurology
Basal ganglia microcircuits offer clues to Parkinson’s symptoms
MDedge Neurology
Potential first-in-class, targeted therapy for myasthenia gravis
MDedge Neurology
Synthetic triglyceride shows potential in Huntington’s disease
MDedge Neurology
Investigative botulinum toxin formulation shows prolonged effect
MDedge Neurology
A safer way to use Botox to treat challenging dystonia type?
MDedge Neurology
Expected spike in acute flaccid myelitis did not occur in 2020
MDedge Neurology
FDA approves new myasthenia gravis drug
MDedge Neurology